FDA approves 2 new protease inhibitors: ritonavir (Norvir) and Crixivan (Indinavir sulfate). Food and Drug Administration

STEP Perspect. 1996 Spring;8(1):7-8.

Abstract

AIDS: The Food and Drug Administration (FDA) approved two new protease inhibitors for treatment of AIDS. Ritonavir (Norvir) and indinavir (Crixivan) have been approved for both monotherapy and combination therapy, and appear to have relatively few side effects. Reports on clinical trials of both drugs are reported. Saquinavir (Invirase) also has FDA approval, but currently has a low absorption rate; better formulations are expected to increase absorption. Early trials indicate that triple drug combinations may suppress HIV replication to very low levels.

Publication types

  • Newspaper Article

MeSH terms

  • Drug Approval
  • Drug Therapy, Combination
  • HIV Infections / drug therapy
  • HIV Infections / virology
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / therapeutic use*
  • Humans
  • Indinavir
  • Pyridines* / administration & dosage
  • Pyridines* / therapeutic use*
  • Ritonavir
  • Thiazoles / administration & dosage
  • Thiazoles / therapeutic use*
  • United States
  • United States Food and Drug Administration
  • Valine / administration & dosage
  • Valine / therapeutic use*

Substances

  • HIV Protease Inhibitors
  • Pyridines
  • Thiazoles
  • Indinavir
  • Valine
  • Ritonavir